Pharma Mar SA (PMRA) Price & Analysis

0 Followers

PMRA Stock Chart & Stats

€80.45

€1.50(1.90%)

At close: Jul 31 4:00 PM EDT

€80.45

€1.50(1.90%)

Day’s Range― - ―

52-Week Range€65.50 - €105.60

Previous CloseN/A

Volume0.00

Average Volume (3M)1.00

Market Cap

€1.21B

Enterprise Value€1.18B

Total Cash (Recent Filing)€168.88M

Total Debt (Recent Filing)€45.84M

Price to Earnings (P/E)20.9

Beta0.54

Next Earnings

Nov 04, 2026

EPS Estimate

0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.26

Shares Outstanding18,000,000

10 Day Avg. Volume0

30 Day Avg. Volume1

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)5.12

Price to Sales (P/S)5.82

P/FCF Ratio29.46

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€100.00

Price Target Upside24.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)1.81

Revenue Forecast (FY)€212.28M

Bulls Say, Bears Say

Bulls Say

High ProfitabilityVery high gross and net margins indicate that Pharma Mar’s approved-product and partnering economics can generate substantial value from revenue. If maintained, this profitability provides resources for oncology research, commercialization, and business development while supporting resilience through normal operating fluctuations.

Conservative Balance SheetLow leverage and a substantial equity base give Pharma Mar financial flexibility to fund its pipeline and absorb changes in operating performance without heavy debt-service pressure. This conservative capital structure can support strategic investment and reduce balance-sheet risk over the coming quarters.

Recent Cash GenerationPositive operating and free cash flow show that recent reported earnings are translating into internally generated funds. This strengthens the company’s ability to finance research, commercialization, and partner activities while reducing reliance on external capital during the next several months.

Bears Say

Inconsistent Revenue GrowthThe recent revenue decline shows that commercial performance has not followed a consistently upward path, despite the 2025 rebound. Uneven top-line development can limit operating leverage, make resource planning harder, and increase reliance on individual products or partnership outcomes.

Volatile Cash ConversionAlthough current cash generation is positive, the history of negative free cash flow and the latest year-over-year decline demonstrate that conversion can fluctuate materially. This may create uneven capacity to fund pipeline investment and could make future cash resources less predictable.

Earnings VolatilityThe large swings in net income, including negative EBIT in 2023, indicate that profitability is sensitive to operating conditions and may not progress smoothly. Such variability can complicate forecasting, make returns less dependable, and weaken confidence in near-term earnings durability.

Pharma Mar SA News

Pharma Mar Continues September Share Buyback on Madrid Exchange

An announcement from Pharma Mar SA ( ($ES:PHM) ) is now available. Pharma Mar has continued its previously...

11d ago

Pharma Mar Wins U.K. Approval for Zepzelca Combo in Small-Cell Lung Cancer

Pharma Mar SA ( ($ES:PHM) ) has shared an announcement. Pharma Mar has secured authorization from the U.K....

18d ago

Pharma Mar Details August Share Buyback Transactions on Madrid Bourse

Pharma Mar SA ( ($ES:PHM) ) has provided an announcement. Pharma Mar has reported the latest tranche of...

1M ago

Pharma Mar Flags Planned Loss of Zepzelca Second-Line SCLC Indication

An update from Pharma Mar SA ( ($ES:PHM) ) is now available. Pharma Mar said its partner Jazz...

2M ago

Pharma Mar Wins New Global Approvals for Zepzelca Lung Cancer Regimen

Pharma Mar SA ( ($ES:PHM) ) has provided an update. Pharma Mar has secured approvals in Canada, Qatar...

2M ago

Pharma Mar Steps Up July Share Buybacks on Madrid Market

Pharma Mar SA ( ($ES:PHM) ) just unveiled an update. Pharma Mar has continued its previously announced share...

2M ago

Pharma Mar Board Endorses 2026 Half-Year Financial Report

Pharma Mar SA ( ($ES:PHM) ) has shared an update. Pharma Mar, S.A. has released its half-year financial...

3M ago

PharmaMar Grows Recurring Revenue as EU Approval Boosts Zepzelca Outlook

The latest announcement is out from Pharma Mar SA ( ($ES:PHM) ). Grupo PharmaMar reported an 18% rise...

3M ago

Pharma Mar Board Approves 2026 Half-Year Financial Report

The latest update is out from Pharma Mar SA ( ($ES:PHM) ). Pharma Mar, S.A. has filed its...

3M ago

Pharma Mar Board Appointment Lapses, Governance Structure Unchanged

The latest update is out from Pharma Mar SA ( ($ES:PHM) ). Pharma Mar has confirmed that the...

3M ago

Pharma Mar price target lowered to EUR 100 from EUR 120 at Chardan

Chardan lowered the firm’s price target on Pharma Mar (PHMMF) to EUR 100 from EUR 120 and keeps...

4M ago

Pharma Mar initiated with a Buy at BTIG

BTIG initiated coverage of Pharma Mar (PHMMF) with a Buy rating and EUR 121 price target The current...

6M ago

Pharma Mar downgraded to Neutral from Outperform at Oddo BHF

Oddo BHF analyst Juan Ros Padilla downgraded Pharma Mar to Neutral from Outperform with a EUR 48 price...

2y ago

Pharma Mar initiated with a Buy at Chardan

Chardan initiated coverage of Pharma Mar with a Buy rating and EUR 60 price target. The analyst cites...

2y ago

PMRA FAQ

What was Pharma Mar SA’s price range in the past 12 months?

Pharma Mar SA lowest stock price was €65.50 and its highest was €105.60 in the past 12 months.

What is Pharma Mar SA’s market cap?

Pharma Mar SA’s market cap is €1.21B.

When is Pharma Mar SA’s upcoming earnings report date?

Pharma Mar SA’s upcoming earnings report date is Nov 04, 2026 which is in 22 days.

How were Pharma Mar SA’s earnings last quarter?

Pharma Mar SA released its earnings results on Jul 29, 2026. The company reported -€0.06 earnings per share for the quarter, missing the consensus estimate of €0.178 by -€0.238.

Is Pharma Mar SA overvalued?

According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharma Mar SA pay dividends?

Pharma Mar SA does not currently pay dividends.

What is Pharma Mar SA’s EPS estimate?

Pharma Mar SA’s EPS estimate is 0.01.

How many shares outstanding does Pharma Mar SA have?

Pharma Mar SA has 18,000,000 shares outstanding.

What happened to Pharma Mar SA’s price movement after its last earnings report?

Pharma Mar SA reported an EPS of -€0.06 in its last earnings report, missing expectations of €0.178. Following the earnings report the stock price went down -2.005%.

Which hedge fund is a major shareholder of Pharma Mar SA?

Currently, no hedge funds are holding shares in DE:PMRA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharma Mar SA Stock Smart Score

Neutral

Fundamentals

Return on Equity

23.64%

Trailing 12-Months

Asset Growth

10.08%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.

Pharma Mar SA (PMRA) Earnings & Revenues

Historic Earnings Reports

PMRA Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all DE:PMRA earnings summaries

PMRA Stock 12 Month Forecast

Average Price Target

€100.00

▲(24.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"71":"€71","86":"€86","101":"€101","78.5":"€78.5","93.5":"€93.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[71,78.5,86,93.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.85,74.93846153846154,77.02692307692307,79.11538461538461,81.20384615384614,83.29230769230769,85.38076923076923,87.46923076923076,89.5576923076923,91.64615384615385,93.73461538461538,95.82307692307693,97.91153846153847,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.85,74.93846153846154,77.02692307692307,79.11538461538461,81.20384615384614,83.29230769230769,85.38076923076923,87.46923076923076,89.5576923076923,91.64615384615385,93.73461538461538,95.82307692307693,97.91153846153847,{"y":100,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.85,74.93846153846154,77.02692307692307,79.11538461538461,81.20384615384614,83.29230769230769,85.38076923076923,87.46923076923076,89.5576923076923,91.64615384615385,93.73461538461538,95.82307692307693,97.91153846153847,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.041,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.881,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.424,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":76.696,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":77.831,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.339,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.907,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.325,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.45,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.25,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.85,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >